XML 48 R42.htm IDEA: XBRL DOCUMENT v3.25.3
License and Collaboration Arrangements (Additional Information) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development expense $ 13,670 $ 3,551 $ 26,049 $ 9,989  
Accounts receivable 30,167   30,167   $ 20,392
Deferred revenue 13,571   13,571   1,126
Other accrued liabilities 21,607   21,607   29,999
Zai Lab          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue recognized       8,000  
Deferred revenue 10,400   10,400    
Other accrued liabilities         5,300
Zai Lab | Interim Supply Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts receivable 7,400   7,400   600
Amount on net product sales recognized 14,900 5,500 17,400 5,500  
Zai Lab | Amended Zai Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue recognized 400 800 1,000 7,300  
Accounts receivable 1,400   1,400   1,600
Zai Lab | Manufacturing Stage Transfer Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License revenue recognized 100 3,400 1,000 3,400  
Zai Lab | Research and Development Support | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Future potential milestone payment receivable 91,000   91,000    
Zai Lab | Royalty Revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues 400   1,500    
GARDP Collaboration Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development expense 800 0 800 0  
PAION AG | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Future potential milestone payment receivable 109,500   109,500    
PAION AG | Cost Reimbursement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues 1,300 0 2,700 0  
PAION AG | Royalty Revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues 700 0 $ 1,800 0  
Everest Medicines Limited          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalties payable period after first commercial sale of product     10 years    
Everest Medicines Limited | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales milestone payments receivable 20,000   $ 20,000    
Everest Medicines Limited | Commercial Supply Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues 0 900 $ 1,800 2,600  
Percentage of reimbursed for direct and certain indirect manufacturing costs     110.00%    
Everest Medicines Limited | Royalty Revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenues   600 $ 2,000 2,300  
George Washington University | GIAPREZA          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of royalty payable on net sales     6.00%    
Percentage of royalty on payments received from sublicensees     15.00%    
Royalty expense 1,100 1,000 $ 3,300 2,500  
Harvard University          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Percentage of royalty payable on net sales     5.00%    
Percentage of royalty on payments received from sublicensees     20.00%    
Percentage of minimum royalty rate     4.50%    
Percentage of maximum royalty based on achievement of annual net product sales thresholds     7.50%    
Royalty expense 300 300 $ 1,000 1,500  
Harvard University | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Clinical development and regulatory milestones amount payable     15,100    
Basilea          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Upfront payment under intangible asset         $ 4,000
Astrazeneca | Durlobactam          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
One-time Milestone Payment on Net Sales     $ 5,000    
Term of Milestone Payment for Net Sales     3 months    
Royalty expense 0 $ 0 $ 0 $ 0  
Astrazeneca | Zoliflodacin          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
One-time Milestone Payment on Commercial Sales     $ 10,000    
Term of Milestone Payment for Commercial Sale     2 years    
Massachusetts Institute of Technology          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Upfront fee payment     $ 500    
Massachusetts Institute of Technology | Development, Regulatory and Sales Milestone | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Future potential milestone payment receivable $ 17,500   $ 17,500